Your email has been successfully added to our mailing list.

×
0.0238461538461539 0.123076923076923 0.0641025641025642 -0.0769230769230769 -0.102820512820513 -0.0517948717948718 -0.0515384615384614 -0.0766666666666666
Stock impact report

Conatus Pharma to explore options, liver disease drug fails trial [Reuters (UK)]

CONATUS PHARMACEUTICALS INC (CNAT) 
Last conatus pharmaceuticals inc earnings: 11/5 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.conatuspharma.com/investor-relations
Company Research Source: Reuters
Conatus Pharma to explore options, liver disease drug fails trial - Reuters 1 Min Read (Reuters) - Conatus Pharmaceuticals Inc said on Monday it will cut staff by about 40% as part of a restructuring plan and explore options. Separately, the company said it is discontinuing the development of its liver disease drug, emricasan, after it failed to meet the main goal in a mid-stage study. Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Arun Koyyur All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2019 Reuters. All Rights Reserved. Show less Read more
Impact Snapshot
Event Time:
CNAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CNAT alerts
Opt-in for
CNAT alerts

from News Quantified
Opt-in for
CNAT alerts

from News Quantified